ArticleFrontiers in bioengineering and biotechnology2026
Combined treatment of spinal cord injury using channeled Porous-GelMA scaffold loaded with genetically engineered MSCs expressing inducible ChABC and constitutive BDNF.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Following spinal cord injury (SCI), glial scarring mediated by chondroitin sulfate proteoglycans (CSPGs), coupled with insufficient neurotrophic support, hinders axonal regeneration. Furthermore, the lack of physical support at the injury site during the acute phase compromises cell survival and engraftment. To overcome these challenges, we developed a three-dimensional channeled porous-GelMA scaffold (CPGS) that provides spatial guidance and structural support. This scaffold is integrated with genetically engineered MSCs designed to continuously release brain-derived neurotrophic factor (BDNF) and inducibly express Chondroitinase ABC (ChABC). This integrated system combines therapeutic factors, stem cells, and tissue engineering to improve the injured microenvironment and promote neural regeneration after SCI. Methods: MSCs were genetically engineered for continuous BDNF expression and doxycycline (Dox)-inducible ChABC expression. RT-qPCR and Western blotting were used to validate expression levels. We performed transcriptomic analysis and protein-level verification to assess the activation of key signaling pathways. A porous GelMA-based CPGS, featuring longitudinal guidance cues, was fabricated and characterized for its structure and mechanical properties. BDNF/ChABC-MSCs were then seeded into the CPGS to create an integrated system, which was subsequently evaluated in a rat SCI model. Results: The BDNF/ChABC-MSCs successfully expressed BDNF and Dox-inducible ChABC, leading to the activation of mTOR, Hedgehog, FAK, and MAPK signaling pathways, as demonstrated by transcriptomic profiling and confirmed at the protein level. The CPGS exhibited longitudinal guidance and favorable mechanical properties. Conclusion: The BDNF/ChABC-MSCs-CPGS integrated system enhances the SCI lesion microenvironment through structural guidance and biochemical modulation, thereby promoting axonal regeneration and functional recovery. This approach presents a novel strategy for combined tissue engineering and stem cell therapy in SCI treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.